1 September 2024

Starpharma signs new DEP® partnership with Chase Sun

 

  • Starpharma signs new DEP® partnership with leading Chinese company Tianjin Chase Sun Pharmaceutical Co., Ltd.
  • Starpharma will utilise its DEP® technology to develop a range of DEP® nanoparticle formulations for Chase Sun
  • Initial project is for the development of DEP® conjugates for an anti-infective drug, with an ability to add additional programs in other therapeutic areas

Melbourne, Australia; 17 August 2020: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it has signed a new research partnership with leading Chinese Pharmaceutical company Tianjin Chase Sun Pharmaceutical Co., Ltd[1]. (stock code 300026; Chase Sun), to develop several DEP® nanoparticle formulations for an anti-infective drug. The agreement also provides for the potential to conduct additional DEP® programs, which can be across therapeutic areas beyond anti-infectives.

Under this new DEP® partnership, Starpharma will initially develop DEP® nanoparticle formulations for an anti-infective product for Chase Sun with the view of enhancing its performance and expanding its therapeutic utility. Chase Sun will fund all activities under this agreement and all costs associated with the further development of any DEP® product. In the event that Chase Sun wishes to commercialise any of the resultant DEP® products, a DEP® licence agreement will be entered into with Starpharma.

Dr Jackie Fairley, Starpharma CEO, commented: “We are delighted to sign this new DEP® partnership with Chase Sun. Chase Sun are a rapidly growing and innovative company in an important global market. This agreement illustrates the broad applicability of the DEP® platform and will further develop the commercial potential of DEP® in the anti-infective space, a therapeutic area of growing interest and need.”

Chase Sun is a leading listed Chinese pharmaceutical company focussed on R&D and commercialisation of healthcare products and operates in one of the largest markets in the world, with more than 6,000 employees. Chase Sun’s market capitalisation exceeds A$3 billion (stock code 300026) and its 2019 sales were in excess of A$1.012 billion.

Download full announcement: Starpharma signs new DEP® partnership with Chase Sun (PDF 58kb)

[1] Tianjin Chase Sun Pharmaceutical Co., Ltd and Australia Chase Sun Pty Ltd

This contains certain forward-looking statements.

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.